Special Issues

Special Issue Title: Drug-Coated balloons-The “leave nothing behind” strategy

· Print Special Issue Flyer

· Deadline for manuscript submissions: 30 September 2021

Special Issue Editor

Guest Editor

Dr. Bernardo Cortese

Cardiovascular Research Team, San Carlo Clinic, Milan, Italy; Fondazione Ricerca e Innovazione Cardiovascolare, Milano, Italy

Website | E-Mail

Interests: Percutaneous tricuspid interventions; Conduction disturbances after TAVI; Antithrombotic therapy in TAVI patients; Percutaneous treatment of bicuspid valve

Special Issue Information

Dear Colleagues,

Interventional cardiology is evolving rapidly with an increased need for better results in treatment of coronary artery disease (CAD) which is the leading cause of death worldwide.
The introduction of drug eluting stents (DES) revolutionized treatment of coronary artery disease by reducing the rate of restenosis to 5%-10%. However, the use of DES in complex patients such as diabetic, small vessel disease, long lesions and coronary artery bypass grafting is still associated with higher risk of ISR.
In recent years, drug-coated balloons (DCB) have emerged as a potential alternative to combat restenosis and fulfill the goal of the DES without duplicating the limitations encountered with previously available devices. With currently available paclitaxel and sirolimus balloon coatings DCBs are showing non-inferiority vs DES in different patient settings. However, a major challenge in the management of coronary artery disease is the accurate identification of those patients who will benefit from either DCB or DES and which coating outperforms the other at long term.

CAD has an increasing incidence, prevalence and mortality rate. In light of recent advances in various delivering and coating devices for management of CAD we introduce this series of concise reviews that will focus on the contemporary management of these patients and investigate different approaches of their care.

Dr. Bernardo Cortese

Guest Editor


Manuscript Submission Information

Manuscripts should be submitted online at https://rcm.imrpress.org by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Reviews in Cardiovascular Medicine is an international peer-reviewed open access quarterly journal published by IMR Press.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is $1950. Submitted papers should be well formatted and use good English.


DCB; Paclitaxel; Sirolimus; Chip patients 

Share This Special Issue


Planned Papers

Title: Rationale for the use of DCBs for the treatment of ISR: everything starts from a correct understanding of the disease

Title: An overview of DCBs for peripheral applications in 2021

Title: Is a highly calcific burden an indication, or a contraindication for DCB? 

Title: DCB for the management of chronic total occlusions

Title: Should paclitaxel be considered an old generation DCB? The limus-era

Title: DCBs as an adjuvant tool to DES for very complex coronary lesions

Please wait a minute...
For Selected: Toggle Thumbnails
Progress on developing an effective below-the-knee drug-coated balloon
Rym El Khoury, Marianne Brodmann, Peter A. Schneider
Reviews in Cardiovascular Medicine    2021, 22 (3): 585-595.   DOI: 10.31083/j.rcm2203070
Abstract343)   HTML39)    PDF(pc) (472KB)(340)       Save
Infrapopliteal atherosclerotic disease continues to present the greatest conundrum for effective endovascular therapies. To date, conventional angioplasty has been fraught with early restenosis and recoil in these complex, long, calcified, and occlusive lesions. The success of metallic drug-eluting stents in coronary arteries has not carried over to below-the-knee arteries. Initial promise in paclitaxel-coated balloons has not been demonstrated in large randomized clinical trials. Furthermore, the potential association between paclitaxel and mortality continues to generate tremendous controversy. The goal of this review article is to discuss the evolution and challenges of drug-coated balloon (DCB) science, present the clinical results of currently available tibial DCBs, and introduce new horizons in DCB technology.
Related Articles | Metrics

Current Issue

  • Volume 22, Issue 3